Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
Krystal Biotech (NASDAQ: KRYS) announced that its CEO, Krish S. Krishnan, will participate in two upcoming conferences: H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) announced that its CEO, Krish S. Krishnan, will participate in two upcoming conferences: H.C. Wainwright's Gene Therapy and Gene Editing Conference on March 30, 2022, at 7:00 a.m. EDT and Guggenheim's 3rd Annual Genomic Medicines and Rare Disease Day on March 31, 2022, from 2:00 to 2:45 p.m. EDT. Webcasts of the presentations will be available, with links to access them provided in the press release. Krystal Biotech focuses on redosable gene therapy for serious diseases, leveraging proprietary technology for potential life-changing treatments.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was +3.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and Guggenheim’s 3rd Annual Genomic Medicines and Rare Disease Day.
Details for the events are as follows:
| H.C. Wainwright Gene Therapy and Gene Editing Conference | ||
| Presentation Date: | Wednesday, March 30, 2022 | |
| Presentation Time: | 7:00 a.m. EDT | |
| Webcast Link: | https://journey.ct.events/view/5be9c8c9-116d-4777-b0f7-afc3aa88fd82 | |
A webcast of the presentation will be available for 90 days beginning at 7:00 a.m. on March 30. It will also be posted in the Investors section of the Krystal Biotech website.
| Guggenheim 3rd Annual Genomic Medicines and Rare Disease Day | ||
| Fireside Chat Date: | Thursday, March 31, 2022 | |
| Fireside Chat Time: | 2-2:45 p.m. EDT | |
| Webcast and Replay Link: | https://kvgo.com/guggenheim/krystal-biotech-inc-march-2022 | |
A replay of the fireside chat will be available via a link on the Krystal Biotech website approximately 48 hours after the event and will be viewable for 1 year.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to potentially bring life-changing treatment options to patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACTS:
Investors:
Whitney Ijem
Krystal Biotech
wijem@krystalbio.com
Media:
Tiffany Hamilton
Krystal Biotech
thamilton@krystalbio.com
Source: Krystal Biotech, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.